Court issues permanent injunction against NeoGenomics' RaDaR test, case enters new phase

AUSTIN, Texas, September 23, 2024–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today issued the following statement in response to inquiries regarding its ongoing patent infringement litigation with NeoGenomics:

On September 23, 2024, the District Court for the Middle District of North Carolina issued a permanent preliminary injunction against NeoGenomics' RaDaR test, which was provisionally lifted in December 2023. Natera continues to pursue its lawsuit against a modified version of RaDaR for infringement of Natera's '454 patent. Natera is seeking comprehensive remedies, including a preliminary injunction, after the Patent Office denied NeoGenomics' motion for inter partes review challenging the validity of the '454 patent.

About Natera

Natera^TM is a global leader in cell-free DNA and genetic testing with a focus on oncology, women's health and organ health. Our goal is to make personalized genetic testing and diagnostics part of standard of care to protect health and enable earlier, more targeted interventions that contribute to longer, healthier lives. Natera's tests are validated by more than 200 peer-reviewed publications demonstrating high accuracy. Natera operates ISO 13485 certified and CAP accredited laboratories in Austin, Texas and San Carlos, California that are certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit www.natera.com.

Forward-looking statements

All statements included in this press release, other than statements of historical fact, are forward-looking statements and do not constitute a representation that Natera's plans, estimates or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in any disputes or litigation or the scope of protection we establish and maintain for our intellectual property or other proprietary rights, and developments or disputes relating thereto. Additional risks and uncertainties are discussed more fully under “Risk Factors” in Natera's most recent filings on Forms 10-K and 10-Q and in other filings that Natera files from time to time with the SEC. These documents are available at www.natera.com/investors and www.sec.gov.

View original version on businesswire.com: https://www.businesswire.com/news/home/20240923199827/en/

The story continues

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, [email protected]

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]